{"pmid":32289517,"title":"LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19.","text":["LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19.","J Thorac Oncol","Cafarotti, Stefano","Patella, Miriam","32289517"],"journal":"J Thorac Oncol","authors":["Cafarotti, Stefano","Patella, Miriam"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289517","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jtho.2020.03.027","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664071627158061056,"score":8.233237,"similar":[{"pmid":32105052,"title":"[Surgical treatment for esophageal cancer during the outbreak of COVID-19].","text":["[Surgical treatment for esophageal cancer during the outbreak of COVID-19].","Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19. COVID-19 spread rapidly nationwide and abroad. The COVID-19 has brought huge impacts to all the people and walks of life, especially to the medical and health systems. It has also brought great challenges to the treatment of patients with cancer. Esophageal cancer is a common malignant tumor in China and most of the patients are in the middle and advanced stage when diagnosed, with immunosuppressive and poor prognosis. The selection of surgical procedures and perioperative managements of esophageal cancer require all thoracic surgeons work together to figure out a reasonable system of surgical treatment and emergency response.","Zhonghua Zhong Liu Za Zhi","Li, Y","Qin, J J","Wang, Z","Yu, Y","Wen, Y Y","Chen, X K","Liu, W X","Li, Y","32105052"],"abstract":["Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19. COVID-19 spread rapidly nationwide and abroad. The COVID-19 has brought huge impacts to all the people and walks of life, especially to the medical and health systems. It has also brought great challenges to the treatment of patients with cancer. Esophageal cancer is a common malignant tumor in China and most of the patients are in the middle and advanced stage when diagnosed, with immunosuppressive and poor prognosis. The selection of surgical procedures and perioperative managements of esophageal cancer require all thoracic surgeons work together to figure out a reasonable system of surgical treatment and emergency response."],"journal":"Zhonghua Zhong Liu Za Zhi","authors":["Li, Y","Qin, J J","Wang, Z","Yu, Y","Wen, Y Y","Chen, X K","Liu, W X","Li, Y"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105052","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112152-20200226-00128","keywords":["COVID-19","Diagnosis and treatment strategy","Esophageal neoplasms","Surgery"],"source":"PubMed","locations":["China","thoracic","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352134437961728,"score":46.13746},{"pmid":32247066,"pmcid":"PMC7118621","title":"Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","text":["Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.","J Gynecol Obstet Hum Reprod","Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril","32247066"],"abstract":["INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance."],"journal":"J Gynecol Obstet Hum Reprod","authors":["Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247066","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jogoh.2020.101729","keywords":["COVID-19","Guideline","Gynaecological cancer","Management"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1663352136154480640,"score":45.710045},{"pmid":32291968,"title":"Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic.","text":["Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic.","Since its outbreak in December 2019 in China, the novel coronavirus disease (COVID-19) has rapidly spread and affected several countries. It has resulted in a difficult situation for cancer patients owing to the risks of the epidemic situation outbreak as well as cancer. Patients with cancer are more likely than the general population to contract COVID-19 because of the systemic immunosuppressive status caused by malignant diseases or anticancer treatment. Lung cancer has the highest morbidity and mortality in China and the world. Most patients with lung cancer are smokers with poor underlying lung conditions and low immunity, thus it is vital to protect them from epidemic diseases during cancer treatment. It is necessary to provide individualized medical treatment and management of treatment-related adverse events for patients with lung cancer based on patients' conditions and regional epidemic patterns.","Thorac Cancer","Zhao, Zhe","Bai, Hua","Duan, Jianchun","Wang, Jie","32291968"],"abstract":["Since its outbreak in December 2019 in China, the novel coronavirus disease (COVID-19) has rapidly spread and affected several countries. It has resulted in a difficult situation for cancer patients owing to the risks of the epidemic situation outbreak as well as cancer. Patients with cancer are more likely than the general population to contract COVID-19 because of the systemic immunosuppressive status caused by malignant diseases or anticancer treatment. Lung cancer has the highest morbidity and mortality in China and the world. Most patients with lung cancer are smokers with poor underlying lung conditions and low immunity, thus it is vital to protect them from epidemic diseases during cancer treatment. It is necessary to provide individualized medical treatment and management of treatment-related adverse events for patients with lung cancer based on patients' conditions and regional epidemic patterns."],"journal":"Thorac Cancer","authors":["Zhao, Zhe","Bai, Hua","Duan, Jianchun","Wang, Jie"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291968","week":"202016|Apr 13 - Apr 19","doi":"10.1111/1759-7714.13424","keywords":["COVID-19","lung neoplasms","therapeutics"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295668899841,"score":42.624424},{"pmid":32077441,"title":"[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].","text":["[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].","Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.","Zhongguo Fei Ai Za Zhi","Xu, Yan","Liu, Hongsheng","Hu, Ke","Wang, Mengzhao","32077441"],"abstract":["Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19."],"journal":"Zhongguo Fei Ai Za Zhi","authors":["Xu, Yan","Liu, Hongsheng","Hu, Ke","Wang, Mengzhao"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32077441","week":"20208|Feb 17 - Feb 23","doi":"10.3779/j.issn.1009-3419.2020.03.02","keywords":["*2019 novel coronavirus disease","*Lung neoplasms","*Patient management"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352134582665216,"score":42.21552},{"pmid":32278368,"title":"Challenges in lung cancer therapy during the COVID-19 pandemic.","text":["Challenges in lung cancer therapy during the COVID-19 pandemic.","Lancet Respir Med","Calabro, Luana","Peters, Solange","Soria, Jean-Charles","Di Giacomo, Anna Maria","Barlesi, Fabrice","Covre, Alessia","Altomonte, Maresa","Vegni, Virginia","Gridelli, Cesare","Reck, Martin","Rizvi, Naiyer","Maio, Michele","32278368"],"journal":"Lancet Respir Med","authors":["Calabro, Luana","Peters, Solange","Soria, Jean-Charles","Di Giacomo, Anna Maria","Barlesi, Fabrice","Covre, Alessia","Altomonte, Maresa","Vegni, Virginia","Gridelli, Cesare","Reck, Martin","Rizvi, Naiyer","Maio, Michele"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278368","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S2213-2600(20)30170-3","source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1663890921975971840,"score":41.32305}]}